MD and Your Heart Monitor: 6 Things I Wish I'd Known
WEBJan 23, 2018 · 1. Use lotion to remove adhesive. Lotion is the easiest way to remove the adhesive on your skin left from the stickers that connect to the electrodes. It is also the least irritating for your skin, especially if you have sensitive skin like me. Let the lotion sink into your skin before wiping of the adhesive with some tissue paper.
Muscular Dystrophy News Home | Muscular Dystrophy News
WEBOct 1, 2024 · Treatment with exon 53-skipping therapy WVE-N531 led to significant increases in muscle dystrophin levels along with signs of improved muscle health and regeneration in boys with Duchenne muscular dystrophy (DMD). That’s according to new six-month interim data from the Phase 1b/2a FORWARD-53 …
End Of An Era: MDA Telethon Ends Historic Run, Urgent Fight for...
WEBMay 6, 2015 · The Muscular Dystrophy Association (MDA) announced May 1 that after careful consideration and analysis of evolving realities pertaining to both television viewing habits and to philanthropic giving, it is time for the organization to discontinue producing and broadcasting the MDA telethon after 58 years on the air, and move beyond its historic Labor Day telethon — most recently named the ...
Losmapimod Fails at FSHD Trial’s Primary Goal, But Shows Potential
WEBJun 29, 2021 · Losmapimod, given twice daily at 15 mg, was randomly assigned to 40 patients, and a placebo tablet to the remaining 40. The mean age of all participants was 45.7 years. The trial’s primary goal was a change from pre-treatment (baseline) in DUX4 -driven gene activity in affected muscles via biopsies assessed at week 16 or 36.
#MDA2022 – DMD Gene Therapy PF-06939926 Safe at High Dose: …
WEBMar 17, 2022 · Treatment with PF-06939926, an experimental gene therapy for Duchenne muscular dystrophy (DMD), was generally well-tolerated among ambulatory patients — boys able to walk — in a Phase 1B clinical trial. Data also hint at the efficacy of the gene therapy, being developed by Pfizer, with researchers noting …
MDA and Invitae Offer Free Muscular Dystrophy Gene Testing, …
WEBby Mary Chapman April 7, 2020. Invitae and the Muscular Dystrophy Association (MDA) are partnering to expand access to free genetic testing and post-test counseling in the United States and Canada, with a goal of more quickly diagnosing muscular dystrophy. Testing is offered at no charge through Invitae’s Detect Muscular Dystrophy program ...
AOC 1001 Eases Symptoms of DM1, Early Clinical Trial Data Show
WEBDec 15, 2022 · Preclinical studies demonstrated AOC 1001 safely reduced the levels of toxic DMPK mRNA in cells and nonhuman primates.. After receiving clearance from the U.S. Food and Drug Administration (FDA), the company launched the six-month Phase 1/2 MARINA clinical trial (NCT05027269) to evaluate AOC 1001 in adults with DM1.. Administered directly into the bloodstream, participants received a single ...
Potential DMD Therapy Casimersen Shows Promising Phase 3 …
WEBApr 5, 2019 · The Phase 3 ESSENCE trial (NCT02500381), also known as 4045-301, is a global, randomized, double-blind, placebo-controlled study, designed to assess the safety and efficacy of casimersen and golodirsen therapies in DMD patients whose mutations are amenable to exon 45 or 53 skipping. Based on feedback from the FDA, the company performed an ...
'Ordinary Joe' Actor With MD Brings Life to TV Character With...
WEBDec 7, 2021 · The show’s name may be “Ordinary Joe,” but this NBC drama series is proving extraordinary for its authentic depiction of a character with a disability, portrayed by John Gluck, 13, who has collagen VI muscular dystrophy. The show follows Joe Kimbreau, played by actor James Wolk, in three different dimensions based on one decision he made ...
DMD treatment: Exon-skipping therapies - Muscular Dystrophy …
WEBJun 28, 2023 · Approved exon-skipping therapies Exondys 51. Exondys 51 (eteplirsen) was developed by Sarepta Therapeutics as a treatment for DMD patients with mutations amenable to exon 51 skipping. That’s about 13% of all people with DMD. The FDA granted Exondys 51 accelerated approval in 2016. The therapy is administered once weekly via an infusion into the bloodstream that takes 35 minutes to one hour.